文献速递眼底病与葡萄膜炎青光眼

眼部衰老的分子基础:机制、病理与新兴治疗

The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

年龄相关眼病(AREDs,包括AMD、青光眼和糖尿病视网膜病变)是永久性失明的主要原因,现有治疗仅控制临床表现而无法阻止分子进程。本文综述衰老的四大标志——线粒体功能障碍、蛋白稳态丧失、细胞衰老和表观遗传漂移——在不同眼组织中形成交互网络,并导致不同临床表型,同时评估衰老细胞清除药物、线粒体靶向药物和部分表观遗传重编程等新兴疗法。

要点

  • 四大衰老标志在眼组织中形成交互自强化网络,不同组织主导机制不同。
  • RPE中线粒体功能障碍驱动AMD,小梁网中衰老和表观遗传漂移主导青光眼。
  • 神经血管单元中高血糖将同一网络导向代谢-表观遗传放大环路维持糖尿病视网膜病变。

核心结论

  • 靶向衰老基本生物学而非孤立治疗各病,有望通过组合策略恢复组织韧性。

研究设计与样本

  • 综述文章,未报告系统检索范围或样本量。

主要发现

  • 衰老四大标志形成交互自强化网络,不同眼组织路由不同导致 divergent 临床表型。
  • RPE高能量环境中线粒体功能障碍主导并驱动AMD。
  • 机械应力下小梁网中细胞衰老和表观遗传漂移优先导致青光眼。
  • 神经血管单元中慢性高血糖将网络导向代谢-表观遗传放大环路维持糖尿病视网膜病变。

关键数值与推荐

  • 关键干预节点包括NLRP3、p62和NAD⁺代谢。

临床怎么用

  • 提示未来治疗应针对衰老网络关键节点,采用组合策略而非单病种对症管理。

局限性

  • 原文未报告综述的检索范围、纳入标准或证据等级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Age-related eye diseases (AREDs)-including age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy-are leading causes of permanent blindness. Current treatments manage clinical manifestations but do not halt the molecular processes that drive disease progression. This limitation has shifted attention toward "geroscience," a strategy that targets the fundamental biology of aging rather than treating each disease in isolation. Four key hallmarks of aging-mitochondrial dysfunction, loss of proteostasis, cellular senescence, and epigenetic drift-are widely implicated in AREDs. We review evidence that these hallmarks do not act independently; instead, they form an interactive, self-reinforcing network. The way this network engages differs from tissue to tissue. In the high-energy environment of the retinal pigment epithelium, mitochondrial dysfunction dominates and drives AMD. In the mechanically stressed trabecular meshwork (TM), senescence and epigenetic drift take precedence, leading to glaucoma. In the neurovascular unit, chronic hyperglycemia routes the same network into a metabolic-epigenetic amplification loop that sustains diabetic retinopathy. The same aging mechanisms, routed through distinct tissue contexts, thus produce divergent clinical phenotypes. We also evaluate emerging therapies, including senolytics, mitochondria-targeted agents, and partial epigenetic reprogramming, and identify key intervention nodes such as NLRP3, p62, and NAD⁺ metabolism. Dismantling these pathological feedback loops offers a path beyond symptom management toward combination strategies that restore tissue resilience.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zong Y, Fan Q, Qiu S, et al. The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics. Invest Ophthalmol Vis Sci. 2026. PMID: 42405673. doi:10.1167/iovs.67.8.13

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。